Modified iPS Cells Found Effective Against Solid Cancers.

Immune cells derived from human induced pluripotent stem, or iPS, that are genetically modified to produce two specific proteins simultaneously can improve the therapeutic effect against solid cancers.

This may lead to a new treatment for solid tumors, which are difficult to combat with existing cancer immunotherapy using iPS cells.

According to Towards Healthcare, the Japan cell therapy market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 308.08 million in 2026 to approximately USD 2018.85 million by 2035, representing a compound annual growth rate (CAGR) of 23.23% from 2026 to 2035. Growth is driven by the Pharmaceuticals and Medical Devices Agency (PMDA), which offers therapies as the fastest-growing segment, which allow for better scalability and lower costs, conditional, time-limited authorizations for regenerative medical products, speeding up time-to-market.

About Japan Cell Therapy

Japan greenlit the world first stem-cell-based therapy for Parkinson, which uses iPS cells to restore dopamine-producing cells in the brain. This region has created a unique regulatory pathway designed to accelerate access to regenerative therapies.

Under this system, treatment can receive conditional and limited-time approval once safety and early signs of efficacy are demonstrated, even if large clinical trials are still ongoing. This would be the first commercially available iPS cell therapy that is expected to roll out as early as this summer in Japan.

CiRA Prof. Shin Kaneko said, "Taking advantage of the characteristics of iPS cells, we can apply [the latest findings] to a new immunotherapy that can provide high-quality cells for treatment in large quantities and in a stable way."
As Dr. Takahashi stated, “I am pleased that our cell therapy for Parkinson disease has received approval from the Japanese regulatory authorities.”

With a rapidly aging population, Japan has one of the world oldest demographics, leading to a higher prevalence of chronic and degenerative diseases, which drives the demand for innovative and personalized therapies.
A recent report by Towards Healthcare highlights that the Japan cell therapy market is witnessing growth driven by a super-aging population, targeted oncology treatments, and the world most streamlined regulatory pathways for regenerative medicine. The country offers massive commercial opportunities for global biopharma partnerships.